Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 7Terminated 3Unknown 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Lymphoid 9Myeloid 4Plasma cell 3CNS 3Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Breast 1

Conditions

Gastrointestinal Stromal Tumors 1

Interventions

Doxorubicin 25Cyclophosphamide 24pembrolizumab 20Specimen Handling 19Temozolomide 16Magnetic Resonance Spectroscopy 15Surgical Procedures, Operative 14Radiotherapy 13Blood Specimen Collection 13Biopsy 13atezolizumab 12Gemcitabine 12fludarabine 11Vincristine 11Ifosfamide 11X-Rays 8Trabectedin 8Nivolumab 8Irinotecan 8Imatinib Mesylate 8Drug Therapy 8cabozantinib 7Surveys and Questionnaires 7Radiation 7liposomal doxorubicin 5abemaciclib 5Sunitinib 5Standard of Care 5Radiation Dose Hypofractionation 5Dactinomycin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dasatinib × Sarcoma × Clear all
NCT05751733 2023-03-02

Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

Xiangya Hospital of Central South University

Phase NA Recruiting
258 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡